Erin Colleen Boyle

Erin Colleen Boyle

Auto-generated profile, based on publicly available information

Erin Colleen Boyle

Hannover Medical School

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2014 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
OGOhad Gal-Mor
Ohad Gal-Mor
EBErin C. Boyle
Erin C. Boyle
GGGuntram A. Grassl
Guntram A. Grassl
Human infections by the bacterial pathogen Salmonella enterica represent major disease burdens worldwide. This highly ubiquitous species consists of more than 2600 different serovars that can be divided into typhoidal and non-typhoidal Salmonella (NTS) serovars. Despite their genetic similarity, these two groups elicit very different diseases and distinct immune responses in humans. Comparative analyses of the genomes of multiple Salmonella serovars have begun to explain the basis of the variation in disease manifestations. Recent advances in modeling both enteric fever and intestinal gastroenteritis in mice will facilitate investigation into both the bacterial- and host-mediated mechanisms involved in salmonelloses. Understanding the genetic and molecular mechanisms responsible for differences in disease outcome will augment our understanding of Salmonella pathogenesis, host immunity, and the molecular basis of host specificity. This review outlines the differences in epidemiology, clinical manifestations, and the human immune response to typhoidal and NTS infections and summarizes the current thinking on why these differences might exist.

17 April 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
DSDaniel G. Sedding
Daniel G. Sedding
EBErin C. Boyle
Erin C. Boyle
JDJasper A. F. Demandt
Jasper A. F. Demandt
JSJudith Sluimer
Judith Sluimer
JDJochen Dutzmann
Jochen Dutzmann
JBJohann Bauersachs
Johann Bauersachs
Plaque microvascularization and increased endothelial permeability are key players in the development of atherosclerosis, from the initial stages of plaque formation to the occurrence of acute cardiovascular events. First, endothelial dysfunction and increased permeability facilitate the entry of diverse inflammation-triggering molecules and particles such as low-density lipoproteins into the artery wall from the arterial lumen and vasa vasorum (VV). Recognition of entering particles by resident phagocytes in the vessel wall triggers a maladaptive inflammatory response that initiates the process of local plaque formation. The recruitment and accumulation of inflammatory cells and the subsequent release of several cytokines, especially from resident macrophages, stimulate the expansion of existing VV and the formation of new highly permeable microvessels. This, in turn, exacerbates the deposition of pro-inflammatory particles and results in the recruitment of even more inflammatory cells. The progressive accumulation of leukocytes in the intima, which trigger proliferation of smooth muscle cells in the media, results in vessel wall thickening and hypoxia, which further stimulates neoangiogenesis of VV. Ultimately, this highly inflammatory environment damages the fragile plaque microvasculature leading to intraplaque hemorrhage, plaque instability, and eventually, acute cardiovascular events. This review will focus on the pivotal roles of endothelial permeability, neoangiogenesis, and plaque microvascularization by VV during plaque initiation, progression, and rupture. Special emphasis will be given to the underlying molecular mechanisms and potential therapeutic strategies to selectively target these processes.

25 July 2006 in Cellular Microbiology
Verified
Journal Article
Open access
PDF file
EBErin C. Boyle
Erin C. Boyle
NBNat F. Brown
Nat F. Brown
BFB. Brett Finlay
B. Brett Finlay
Salmonella enterica serovar Typhimurium is a major cause of human gastroenteritis. Infection of epithelial monolayers by S. Typhimurium disrupts tight junctions that normally maintain the intestinal barrier and regulate cell polarity. Tight junction disruption is dependent upon the Salmonella pathogenicity island-1 (SPI-1) type 3 secretion system but the specific effectors involved have not been identified. In this study we demonstrate that SopB, SopE, SopE2 and SipA are the SPI-1-secreted effectors responsible for disruption of tight junction structure and function. Tight junction disruption by S. Typhimurium was prevented by inhibiting host protein geranylgeranylation but was not dependent on host protein synthesis or secretion of host-derived products. Unlike wild-type S. Typhimurium, ΔsopB, ΔsopE/E2, ΔsipA, or ΔsipA/sopB mutants, ΔsopB/E/E2 and ΔsipA/sopE/E2 mutants were unable to increase the permeability of polarized epithelial monolayers, did not disrupt the distribution or levels of ZO-1 and occludin, and did not alter cell polarity. These data suggest that SPI-1-secreted effectors utilize their ability to stimulate Rho family GTPases to disrupt tight junction structure and function.

5 May 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
Evgenii RubalskiiEvgenii Rubalskii
Evgenii Rubalskii
Stefan RuemkeStefan Ruemke
Stefan Ruemke
CSChristina Salmoukas
Christina Salmoukas
EBErin C. Boyle
Erin C. Boyle
GWGregor Warnecke
Gregor Warnecke
AHAxel Haverich
Axel Haverich
(1) Objective: Bacterial resistance to conventional antibiotic therapy is an increasingly significant worldwide challenge to human health. The objective is to evaluate whether bacteriophage therapy could complement or be a viable alternative to conventional antibiotic therapy in critical cases of bacterial infection related to cardiothoracic surgery. (2) Methods: Since September 2015, eight patients with multi-drug resistant or especially recalcitrant Staphylococcus aureus, Enterococcus faecium, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli infections were treated with bacteriophage preparations as a therapy of last resort according to Article 37 of the Declaration of Helsinki. Patients had infections associated with immunosuppression after organ transplantation or had infections of vascular grafts, implanted medical devices, and surgical wounds. Individualized phage preparations were administered locally, orally, or via inhalation for different durations depending on the case. All patients remained on conventional antibiotics during bacteriophage treatment. (3) Results: Patients ranged in age from 13 to 66 years old (average 48.5 ± 16.7) with seven males and one female. Eradication of target bacteria was reached in seven of eight patients. No severe adverse side effects were observed. (4) Conclusions: Phage therapy can effectively treat bacterial infections related to cardiothoracic surgery when conventional antibiotic therapy fails.

1 October 2003 in Current Opinion in Cell Biology
Verified
Journal Article
Closed access
EBErin C Boyle
Erin C Boyle
BFB Brett Finlay
B Brett Finlay

1 March 2007 in Journal of Bacteriology
Verified
Journal Article
Closed access
PDF file
EBErin C. Boyle
Erin C. Boyle
JBJennifer L. Bishop
Jennifer L. Bishop
GGGuntram A. Grassl
Guntram A. Grassl
BFB. Brett Finlay
B. Brett Finlay
Although Salmonella enterica serovars are some of the best-studied bacterial pathogens, the field still has a long way to go, especially when one considers that (i) they cause significant morbidity and mortality worldwide; (ii) they have broad host ranges, but for unknown reasons, infections result